FDA approves generic Casodex from Sun, Mylan

07/7/2009 | Forbes

Mylan and Sun Pharmaceutical Industries secured FDA clearance for their generic copies of AstraZeneca's prostate cancer drug Casodex. Total U.S. sales of Casodex reached $322 million for the year that ended March 31, said Mylan, which has begun shipping its bicalutamide tablets.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ